$INSM
INSMED Inc Stock $insm

$insm Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000110465913060111 Filed on August 06, 2013

Income Statement

Concept	2013 Q2	2012 Q2
Revenue	$11.50M	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.540M	$2.240M
YoY Change	236.61%	-18.55%
% of Gross Profit
Research & Development	$12.23M	$7.745M
YoY Change	57.84%	-11.08%
% of Gross Profit
Depreciation & Amortization	$150.0K	$130.0K
YoY Change	15.38%	85.71%
% of Gross Profit
Operating Expenses	$19.77M	$9.983M
YoY Change	98.03%	-12.81%
Operating Profit	-$8.269M	-$9.983M
YoY Change	-17.17%
Interest Expense	$635.0K	$1.000K
YoY Change	63400.0%	-99.78%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00
YoY Change
Pretax Income	-$8.854M	-$9.694M
YoY Change	-8.67%	-3.25%
Income Tax	$0.00	$2.000K
% Of Pretax Income
Net Earnings	-$8.854M	-$9.696M
YoY Change	-8.68%	-3.23%
Net Earnings / Revenue	-76.99%
Basic Earnings Per Share
Diluted Earnings Per Share	-$278.7K	-$389.9K
COMMON SHARES
Basic Shares Outstanding	31.75M shares
Diluted Shares Outstanding	31.75M shares

Balance Sheet

Concept	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.80M	$73.10M
YoY Change	5.06%	-20.54%
Cash & Equivalents	$74.59M	$28.58M
Short-Term Investments		$44.60M
Other Short-Term Assets	$1.800M	$700.0K
YoY Change	157.14%	75.0%
Inventory
Prepaid Expenses
Receivables		$0.00
Other Receivables		$0.00
Total Short-Term Assets	$78.57M	$73.90M
YoY Change	6.31%	-20.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.900M	$1.800M
YoY Change	5.56%	80.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$2.100M
YoY Change		0.0%
Other Assets	$100.0K	$100.0K
YoY Change	0.0%	-75.0%
Total Long-Term Assets	$60.16M	$62.20M
YoY Change	-3.28%	-29.08%
TOTAL ASSETS
Total Short-Term Assets	$78.57M	$73.90M
Total Long-Term Assets	$60.16M	$62.20M
Total Assets	$138.7M	$136.1M
YoY Change	1.93%	-24.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.900M	$3.200M
YoY Change	146.88%	68.42%
Accrued Expenses	$3.188M	$3.000M
YoY Change	6.27%	150.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.700M	$100.0K
YoY Change	4600.0%	0.0%
Total Short-Term Liabilities	$18.10M	$6.500M
YoY Change	178.48%	85.71%
LONG-TERM LIABILITIES
Long-Term Debt	$14.89M	$9.100M
YoY Change	63.67%	9000.0%
Other Long-Term Liabilities	$500.0K	$800.0K
YoY Change	-37.5%
Total Long-Term Liabilities	$14.89M	$9.900M
YoY Change	50.44%	9800.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.10M	$6.500M
Total Long-Term Liabilities	$14.89M	$9.900M
Total Liabilities	$33.00M	$16.30M
YoY Change	102.42%	352.78%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$105.2M	$119.7M
YoY Change
Total Liabilities & Shareholders Equity	$138.7M	$136.1M
YoY Change	1.93%	-24.51%

Cashflow Statement

Concept	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$8.854M	-$9.696M
YoY Change	-8.68%	-3.23%
Depreciation, Depletion And Amortization	$150.0K	$130.0K
YoY Change	15.38%	85.71%
Cash From Operating Activities	-$5.110M	-$7.290M
YoY Change	-29.9%	-33.85%
INVESTING ACTIVITIES
Capital Expenditures	-$330.0K	-$30.00K
YoY Change	1000.0%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$4.150M
YoY Change	-100.0%	-448.74%
Cash From Investing Activities	-$330.0K	$4.120M
YoY Change	-108.01%	-429.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	600.0K	9.690M
YoY Change	-93.81%	96800.0%
NET CHANGE
Cash From Operating Activities	-5.110M	-7.290M
Cash From Investing Activities	-330.0K	4.120M
Cash From Financing Activities	600.0K	9.690M
Net Change In Cash	-4.840M	6.520M
YoY Change	-174.23%	-153.18%
FREE CASH FLOW
Cash From Operating Activities	-$5.110M	-$7.290M
Capital Expenditures	-$330.0K	-$30.00K
Free Cash Flow	-$4.780M	-$7.260M
YoY Change	-34.16%	-33.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Interest Expense InterestExpense	3000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39012357	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90782000	USD
CY2012Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	2153000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	643000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	93578000	USD
CY2012Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	58200000	USD
CY2012Q4	us-gaap	Other Assets OtherAssets	117000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1666000	USD
CY2012Q4	us-gaap	Assets Assets	153561000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7060000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2207000	USD
CY2012Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	295000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	149000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	96000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3007000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15747000	USD
CY2012Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	647000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	64000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16221000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	32679000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31754000	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24875000	shares
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8854000	USD
CY2013Q3	insm	Number Of Initial Indications In Orphan Patient Populations For Which Clinical Trials Conducted NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted	2	item
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	315000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	455325000	USD
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	790000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	120882000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153561000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31488204	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31488204	shares
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	105184000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28575000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14848000	USD
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	290000	USD
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31999760	shares
	us-gaap	Operating Expenses OperatingExpenses	17247000	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	1000	USD
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31999760	shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17247000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	147533	shares
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	12250	shares
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8854000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3036701	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	335412	shares
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9694000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	5000	USD
CY2013Q2	us-gaap	Long Term Debt LongTermDebt	20000000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4763000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	78566000	USD
CY2013Q2	us-gaap	Assets Assets	138725000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74588000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	18101000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138725000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9726000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12484000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	19769000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7745000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	9983000	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2238000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8269000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9983000	USD
CY2013Q2	us-gaap	Debt Current DebtCurrent	-4650000	USD
CY2013Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14894000	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.10
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates -</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.  The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances.  The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each period presented are effected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue recognition, stock-based compensation, income taxes, loss contingencies, the warrant fair value calculation, impairment of intangibles and long lived assets and accounting for research and development costs.  Actual results could differ from those estimates.</font></p> </div>
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9519000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.65
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Concentration of Credit Risk</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">- Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company places its cash equivalents with financial institutions that it believes have high credit quality. The Company has established investment guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company sources each of its raw materials from a single supplier.  In addition, the production of the Company’s lead product candidate is performed by a sole manufacturer. The inability of the suppliers or manufacturer to fulfill supply requirements of the Company could materially adversely affect future operating results or the Company’s business generally. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially adversely affect the Company’s future operating results.</font></p> </div>
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	10451000	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	30000	USD
CY2013Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
CY2013Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22532000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16541000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31654000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24867000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31654000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24867000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	item
CY2012Q4	insm	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	1460000	USD
CY2012Q4	insm	Liability For Stock Based Compensation Awards LiabilityForStockBasedCompensationAwards	1204000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	185000	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	80000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2933000	USD
CY2013Q2	insm	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	2767000	USD
CY2013Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	267000	USD
CY2013Q2	us-gaap	Interest Payable Current InterestPayableCurrent	154000	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3188000	USD
CY2013Q2	us-gaap	Secured Debt SecuredDebt	20000000	USD
CY2013Q2	insm	Additional Charge At End Of Term AdditionalChargeAtEndOfTerm	141000	USD
CY2013Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	144000	USD
CY2013Q2	insm	Unamortized Discount From Warrant UnamortizedDiscountFromWarrant	453000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.37
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16537000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.59
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24867000	shares
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	708000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	12.80
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.62
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.08
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6169988	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5796685	USD
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1147956	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M17D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y9M29D
CY2013Q2	insm	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	3	item
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1817839	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3275156	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1617100	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y7M17D
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1221000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2013Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2012Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.051	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	350000000	USD
CY2013Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2012Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	594000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1201000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	498000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	425000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2718000	USD
	dei	Entity Registrant Name EntityRegistrantName	INSMED INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001104506
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22579000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16355000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22532000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31654000	shares
CY2013Q2	us-gaap	Revenues Revenues	11500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	274000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1013000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	263000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	864000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	236000	USD
	us-gaap	Accretion Expense AccretionExpense	97000	USD
	insm	Increase Decrease In Accrued Lease Expenses IncreaseDecreaseInAccruedLeaseExpenses	-129000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	54000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16321000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	95000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	17051000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	16961000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-491000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	62000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9664000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-16194000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	677000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	618000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	13727000	USD
	us-gaap	Interest Paid InterestPaid	3000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	USD
	us-gaap	Interest Paid InterestPaid	944000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	186000	USD
	us-gaap	Revenues Revenues	11500000	USD

Files In Submission

Name	View Source	Status
0001104659-13-060111-index-headers.html	Edgar Link	pending
0001104659-13-060111-index.html	Edgar Link	pending
0001104659-13-060111.txt	Edgar Link	pending
0001104659-13-060111-xbrl.zip	Edgar Link	pending
a13-14008_110q.htm	Edgar Link	pending
a13-14008_1ex31d1.htm	Edgar Link	pending
a13-14008_1ex31d2.htm	Edgar Link	pending
a13-14008_1ex32d1.htm	Edgar Link	pending
a13-14008_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
insm-20130630.xml	Edgar Link	completed
insm-20130630.xsd	Edgar Link	pending
insm-20130630_cal.xml	Edgar Link	unprocessable
insm-20130630_def.xml	Edgar Link	unprocessable
insm-20130630_lab.xml	Edgar Link	unprocessable
insm-20130630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSM
INSMED Inc Stock $insm

2013 Q2 Form 10-Q Financial Statement

#000110465913060111 Filed on August 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM INSMED Inc Stock $insm

2013 Q2 Form 10-Q Financial Statement

#000110465913060111 Filed on August 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM
INSMED Inc Stock $insm